Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Medical Genetics

Decoding Your Diagnosis: Biopsies and Genetic Reports

At a Glance

For arPEO, genetic testing and, in unresolved cases, muscle biopsy can provide complementary evidence. Muscle may reveal mtDNA deletions, depletion, ragged-red or COX-deficient fibers, while a report should clarify pathogenic variants, their phase, and any VUS.

Navigating the diagnostic process for arPEO can feel like a complex puzzle where the pieces come from different parts of your body. Because the condition involves both your main genetic “master blueprints” (nuclear DNA) and your cell’s “power plant blueprints” (mitochondrial DNA), doctors often need to look at both to get a complete picture [1][2].

The Muscle Biopsy: Seeing the Damage

A muscle biopsy is an option reserved for selected diagnostically unresolved cases of mitochondrial disease, though modern evaluation generally prioritizes comprehensive genetic testing [3]. Blood testing is often appropriate for nuclear-gene testing, whereas detection of mtDNA deletions or depletion may be tissue-dependent. In arPEO, the genetic damage—specifically mtDNA deletions—may be present in your muscles but entirely absent from your blood or saliva [4][5].

When a pathologist looks at your muscle tissue under a microscope, they look for specific “calling cards” of arPEO:

  • Ragged-Red Fibers (RRF): These are muscle fibers that look irregular and “ragged” when a special stain (Gomori trichrome) is applied [6]. This happens because the cell is desperately trying to compensate for low energy by overproducing mitochondria, which then clump together at the edges of the cell [6].
  • COX-Deficient Fibers: Cytochrome c oxidase (COX) is a vital enzyme for energy production. In arPEO, many muscle fibers will test “negative” or “deficient” for this enzyme, appearing as pale or white circles among healthy blue or brown fibers [7][8].
  • Multiple mtDNA Deletions: This is a qualitative finding where pieces of the mitochondrial DNA are literally missing [9]. Finding multiple different deletions usually points toward a defect in a nuclear gene (like POLG or RRM2B) rather than a random error in the mitochondria themselves [10][3].

Reading Your Genetic Report

Your genetic report is the final piece of the puzzle. It identifies the “typo” in your nuclear DNA that started the problem. Here are the key terms you might see:

  • Biallelic Variants: When classified as pathogenic or likely pathogenic, and shown to be on opposite copies (in trans), this confirms the “autosomal recessive” nature of your condition. It means you have two variants (mutations)—one on the copy of the gene you got from your father and one from your mother [11].
  • Compound Heterozygous: This means your two mutations are different from each other (for example, “Typo A” from mom and “Typo B” from dad), but they both affect the same gene [12].
  • VUS (Variant of Uncertain Significance): This is a common and often frustrating result. It means a change was found in a gene, but scientists don’t yet have enough evidence to say for sure if it causes disease or if it’s just a harmless natural variation [13]. A VUS should not be used by itself to diagnose arPEO, direct predictive testing, or make major treatment or reproductive decisions.
  • mtDNA Depletion: Unlike a deletion (missing piece), depletion means the total copy number of mitochondrial DNA is much lower than it should be [14][12].

Diagnostic Completeness Checklist

A complete diagnostic workup for arPEO should ideally include several key pieces of data. You can use this list to ensure your medical records are thorough:

  1. Clinical Phenotype: A description of whether your symptoms are “Pure PEO” (eyes only) or “PEO-Plus” (including balance, hearing, or nerve issues) [3][15].
  2. Tissue Source: Documentation of whether DNA was tested from blood, saliva, or muscle (muscle is most accurate for mtDNA deletions) [2][3].
  3. Nuclear Gene Panel: Results for high-risk genes including POLG, TWNK, RRM2B, and RNASEH1 [10][16].
  4. Pathology Findings: A count or percentage of COX-negative fibers and the presence of ragged-red fibers [7][3].
  5. mtDNA Analysis: Specifics on whether multiple deletions or depletion were detected in the sampled tissue [9][10].

If your genetic testing from blood was “negative” but your symptoms and family history strongly suggest arPEO, a muscle biopsy may be the next step to find the answers that are hidden in your muscle tissue [4][2].

Common questions in this guide

Why might I need a muscle biopsy if my blood genetic test was negative?
A muscle biopsy may be considered when symptoms and family history still suggest arPEO after blood testing is unrevealing. Mitochondrial DNA deletions can be present in muscle but absent from blood or saliva, although comprehensive genetic testing is generally prioritized before biopsy.
What do ragged-red fibers and COX-deficient fibers mean on a muscle biopsy?
Ragged-red fibers reflect an abnormal buildup of mitochondria in muscle cells. COX-deficient fibers have reduced activity of an enzyme needed for energy production. These findings can support mitochondrial disease, but they must be interpreted with the clinical picture and genetic results.
How are mtDNA deletions different from mtDNA depletion?
An mtDNA deletion means that sections of mitochondrial DNA are missing, while depletion means the total number of mitochondrial DNA copies is lower than expected. Multiple mtDNA deletions often suggest a problem in a nuclear gene, but either result needs interpretation in the context of the tissue tested and other findings.
What do biallelic and compound heterozygous variants mean in my report?
Biallelic variants are two disease-causing or likely disease-causing changes in the same gene, one on each copy. Compound heterozygous variants are two different changes in that gene, and they need to be shown to be on opposite copies, or in trans, to support an autosomal recessive diagnosis.
Can a VUS confirm that I have arPEO?
No. A variant of uncertain significance does not have enough evidence to show whether it causes disease, so it should not be used by itself to diagnose arPEO or guide predictive testing, major treatment choices, or reproductive decisions.
What information should a complete arPEO diagnostic report include?
It should document the clinical pattern, the source of the tested DNA, nuclear-gene panel results, muscle biopsy findings such as COX-deficient or ragged-red fibers, and whether mitochondrial DNA deletions or depletion were found. These details help clinicians judge whether the results fit the person's symptoms.

Get notified when new evidence is published on Autosomal recessive progressive external ophthalmoplegia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    Progressive External Ophthalmoplegia in Polish Patients-From Clinical Evaluation to Genetic Confirmation.

    Kierdaszuk B, Kaliszewska M, Rusecka J, et al.

    Genes 2020; (12(1)) doi:10.3390/genes12010054.

    PMID: 33396418
  2. 2

    A novel mitochondrial m.4414T>C MT-TM gene variant causing progressive external ophthalmoplegia and myopathy.

    Hellebrekers DMEI, Blakely EL, Hendrickx ATM, et al.

    Neuromuscular disorders : NMD 2019; (29(9)):693-697 doi:10.1016/j.nmd.2019.08.005.

    PMID: 31488384
  3. 3

    Clinical, pathological and genetic spectrum in 89 cases of mitochondrial progressive external ophthalmoplegia.

    Rodríguez-López C, García-Cárdaba LM, Blázquez A, et al.

    Journal of medical genetics 2020; (57(9)):643-646 doi:10.1136/jmedgenet-2019-106649.

    PMID: 32161153
  4. 4

    Neuropathic Pain as Main Manifestation of POLG-Related Disease: A Case Report.

    Lang-Orsini M, Gonzalez-Perez P

    Frontiers in neurology 2022; (13()):846110 doi:10.3389/fneur.2022.846110.

    PMID: 35350396
  5. 5

    Using urine to diagnose large-scale mtDNA deletions in adult patients.

    Varhaug KN, Nido GS, de Coo I, et al.

    Annals of clinical and translational neurology 2020; (7(8)):1318-1326 doi:10.1002/acn3.51119.

    PMID: 32634300
  6. 6

    Identification of a novel heterozygous guanosine monophosphate reductase (GMPR) variant in a patient with a late-onset disorder of mitochondrial DNA maintenance.

    Sommerville EW, Dalla Rosa I, Rosenberg MM, et al.

    Clinical genetics 2020; (97(2)):276-286 doi:10.1111/cge.13652.

    PMID: 31600844
  7. 7

    Multi-Omics Approach to Mitochondrial DNA Damage in Human Muscle Fibers.

    Elstner M, Olszewski K, Prokisch H, et al.

    International journal of molecular sciences 2021; (22(20)) doi:10.3390/ijms222011080.

    PMID: 34681740
  8. 8

    Genotype-Phenotype Correlation in Progressive External Ophthalmoplegia: Insights From a Retrospective Analysis.

    Wang J, Lin Y, Zhuang X, et al.

    Neuropathology and applied neurobiology 2025; (51(1)):e70001 doi:10.1111/nan.70001.

    PMID: 39822040
  9. 9

    Mitochondrial DNA maintenance defects.

    El-Hattab AW, Craigen WJ, Scaglia F

    Biochimica et biophysica acta. Molecular basis of disease 2017; (1863(6)):1539-1555 doi:10.1016/j.bbadis.2017.02.017.

    PMID: 28215579
  10. 10

    Progressive external ophthalmoplegia.

    Hirano M, Pitceathly RDS

    Handbook of clinical neurology 2023; (194()):9-21 doi:10.1016/B978-0-12-821751-1.00018-X.

    PMID: 36813323
  11. 11

    Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO.

    Hedberg-Oldfors C, Macao B, Basu S, et al.

    Neurology. Genetics 2020; (6(1)):e391 doi:10.1212/NXG.0000000000000391.

    PMID: 32042919
  12. 12

    Whole-Exome Sequencing Identifies a Novel POLG Frameshift Variant in an Adult Patient Presenting with Progressive External Ophthalmoplegia and Mitochondrial DNA Depletion.

    Kurtz J, Fernandes JA, Mansukhani M, et al.

    Case reports in genetics 2021; (2021()):9969071 doi:10.1155/2021/9969071.

    PMID: 34777884
  13. 13

    Variants of uncertain significance in the era of next-generation sequencing.

    Levkova M, Stoyanova M, Benkova-Petrova M, et al.

    Journal of the American Association of Nurse Practitioners 2022; (34(8)):1018-1021 doi:10.1097/JXX.0000000000000745.

    PMID: 35731603
  14. 14

    MtDNA-maintenance defects: syndromes and genes.

    Viscomi C, Zeviani M

    Journal of inherited metabolic disease 2017; (40(4)):587-599 doi:10.1007/s10545-017-0027-5.

    PMID: 28324239
  15. 15

    Novel and recurrent nuclear gene variations in a cohort of Chinese progressive external ophthalmoplegia patients with multiple mtDNA deletions.

    Hou Y, Zhao X, Xie Z, et al.

    Molecular genetics & genomic medicine 2022; (10(5)):e1921 doi:10.1002/mgg3.1921.

    PMID: 35289132
  16. 16

    Case Report: Rare Homozygous RNASEH1 Mutations Associated With Adult-Onset Mitochondrial Encephalomyopathy and Multiple Mitochondrial DNA Deletions.

    Manini A, Caporali L, Meneri M, et al.

    Frontiers in genetics 2022; (13()):906667 doi:10.3389/fgene.2022.906667.

    PMID: 35711919

This page explains arPEO biopsy and genetic-report terms for educational purposes only and does not replace medical advice. Your treating clinician and genetics team should interpret your results and discuss testing or treatment decisions.